Breaking News Instant updates and real-time market news.

SBBP

Strongbridge Biopharma

$8.35

0.35 (4.38%)

, AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

07:33
01/17/18
01/17
07:33
01/17/18
07:33

Strongbridge Biopharma to host conference call

Conference call to discuss the Macrilen acquisition will be held on January 17 at 8:30 am. Webcast Link

SBBP

Strongbridge Biopharma

$8.35

0.35 (4.38%)

AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

  • 17

    Jan

SBBP Strongbridge Biopharma
$8.35

0.35 (4.38%)

08/10/17
OPCO
08/10/17
INITIATION
Target $12
OPCO
Outperform
Strongbridge Biopharma initiated with an Outperform at Oppenheimer
Oppenheimer analyst Hartaj Singh started Strongbridge Biopharma with an Outperform rating and $12 price target. The company's two assets, Keveyis and Recorlev, both have "proven clinical data and prior use in their respective therapeutic categories," the analyst contends. He's "bullish on the story."
08/11/17
08/11/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Strongbridge Biopharma (SBBP) initiated with an Outperform at Oppenheimer. 2. Discovery (DISCA) initiated with a Neutral at Piper Jaffray. 3. MannKind (MNKD) initiated with a Buy at Maxim. 4. Veritone (VERI) initiated with a Buy at Roth Capital. 5. Esperion (ESPR) initiated with a Neutral at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/05/17
CANT
12/05/17
INITIATION
Target $14
CANT
Overweight
Strongbridge Biopharma initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald started Strongbridge Biopharma with an Overweight rating and $14 price target.
12/06/17
CANT
12/06/17
INITIATION
Target $14
CANT
Overweight
Cantor calls Strongbridge 'significantly undervalued' in initiation report
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Strongbridge Biopharma with an Overweight rating and $14 price target. The analyst believes the ongoing commercialization of ultra orphan drug Keveyis in primary periodic paralysis as well as late-stage development of Recorlev in Cushing's makes Strongbridge attractive. Success on either front could drive a "major inflection point for the shares," the analyst contends. Piros views the company as "significantly undervalued."
AEZS Aeterna Zentaris
$2.07

-0.0999 (-4.60%)

05/02/17
MAXM
05/02/17
NO CHANGE
Target $2
MAXM
Buy
Aeterna Zentaris price target lowered to $2 from $11 at Maxim
Maxim analyst Jason Kolbert removed ZoptEC from his Aeterna Zentaris model after the drug's Phase 3 study in metastatic endometrial cancer did not achieve its primary endpoint and cut his price target accordingly to $2 from $11. However, he keeps a Buy rating on Aeterna Zentaris shares as the company moves closer to filing the NDA for Macrilen, which is expected in Q3. Aeterna Zentaris shares fell $2.00, or roughly 60%, to $1.35 yesterday.
07/19/17
MAXM
07/19/17
NO CHANGE
MAXM
Aeterna Zentaris price target raised to $4 from $2 at Maxim
07/20/17
MAXM
07/20/17
NO CHANGE
Target $4
MAXM
Buy
Aeterna Zentaris price target raised to $4 from $2 at Maxim
Maxim analyst Jason Kolbert noted that that the FDA has set a December 30, 2017 PDUFA date for Aeterna Zentaris' Macrilen, which would be the only FDA-approved drug for the assessment of Adult Growth Hormone Deficiency if approved. The analyst, who sees Macrilen as poised to displace the Insulin Tolerance Test, raised his price target on Aeterna shares to $4 from $2 and keeps a Buy rating on the stock.
12/21/17
MAXM
12/21/17
NO CHANGE
Target $4
MAXM
Buy
Aeterna Zentaris' Macrilen could be rapidly adopted, says Maxim
Maxim analyst Jason Kolbert noted that Aeterna Zentaris' Macrilen will be the only FDA-approved drug for the assessment of Adult Growth Hormone Deficiency. He believes, given its advantages over the insulin tolerance test that is currently the standard, that Macrilen could be rapidly adopted by physicians, he tells investors. Kolbert has a Buy rating and $4 price target on Aeterna Zentaris shares, which are up 65% in pre-market trading to $3.30 following the FDA approval announcement last night.

TODAY'S FREE FLY STORIES

BPOP

Popular

$48.97

1.21 (2.53%)

09:51
07/23/18
07/23
09:51
07/23/18
09:51
Hot Stocks
Popular announces $125M stock repurchase plan »

Popular announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ROKU

Roku

$50.54

0.76 (1.53%)

, NFLX

Netflix

$358.65

-2.68 (-0.74%)

09:50
07/23/18
07/23
09:50
07/23/18
09:50
Recommendations
Roku, Netflix analyst commentary  »

Roku price target raised…

ROKU

Roku

$50.54

0.76 (1.53%)

NFLX

Netflix

$358.65

-2.68 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

KR

Kroger

$28.78

0.64 (2.27%)

09:50
07/23/18
07/23
09:50
07/23/18
09:50
Options
Sweep buyers of Kroger short-term calls as shares see relative strength »

Sweep buyers of Kroger…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIYY

Barclays ETN+ FI Enhanced Global High Yield ETN Series B

$98.56

(0.00%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Barclays ETN+ FI Enhanced Global High Yield ETN Series B falls -5.6% »

Barclays ETN+ FI Enhanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$42.60

-2.63 (-5.81%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Halliburton falls -5.7% »

Halliburton is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ITW

Illinois Tool Works

$136.81

-10.04 (-6.84%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Illinois Tool Works falls -6.4% »

Illinois Tool Works is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

EMES

Emerge Energy

$6.99

(0.00%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Emerge Energy rises 5.8% »

Emerge Energy is up 5.8%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

HCLP

Hi-Crush Partners

$12.90

2.05 (18.89%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Hi-Crush Partners rises 19.8% »

Hi-Crush Partners is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

DDE

Dover Downs

$3.04

1 (49.02%)

09:47
07/23/18
07/23
09:47
07/23/18
09:47
Hot Stocks
Dover Downs rises 50.5% »

Dover Downs is up 50.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

BIDU

Baidu

$259.54

-0.46 (-0.18%)

09:45
07/23/18
07/23
09:45
07/23/18
09:45
Downgrade
Baidu rating change  »

Baidu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Sep

MED

Medifast

$171.25

-0.21 (-0.12%)

09:45
07/23/18
07/23
09:45
07/23/18
09:45
Recommendations
Medifast analyst commentary  »

Medifast price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

09:45
07/23/18
07/23
09:45
07/23/18
09:45
General news
Existing Home Sales to be reported at 10:00 »

June Existing Home Sales…

AMZN

Amazon.com

$1,813.84

(0.00%)

09:43
07/23/18
07/23
09:43
07/23/18
09:43
Hot Stocks
Trump calls Washington Post an 'expensive lobbyist' for Amazon »

President Trump tweeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Jul

  • 16

    Aug

ARWR

Arrowhead

$16.02

(0.00%)

09:41
07/23/18
07/23
09:41
07/23/18
09:41
Recommendations
Arrowhead analyst commentary  »

Arrowhead fair value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNC

Tronc

$16.21

(0.00%)

09:41
07/23/18
07/23
09:41
07/23/18
09:41
Periodicals
Tronc seen making 'massive' layoffs at Daily News, NY Post reports »

The Daily News, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$10.85

(0.00%)

, HAS

Hasbro

$94.02

(0.00%)

09:40
07/23/18
07/23
09:40
07/23/18
09:40
Options
Unusually active option classes on open July 23rd »

Unusual total active…

HCLP

Hi-Crush Partners

$10.85

(0.00%)

HAS

Hasbro

$94.02

(0.00%)

DLTR

Dollar Tree

$86.45

(0.00%)

HPE

HP Enterprise

$15.47

(0.00%)

IBB

iShares Nasdaq Biotechnology Index

$118.23

(0.00%)

HAL

Halliburton

$45.23

(0.00%)

RHT

Red Hat

$147.89

(0.00%)

XLF

Financial Select Sector

$27.57

(0.00%)

BMY

Bristol-Myers

$56.71

(0.00%)

TSLA

Tesla

$313.49

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 07

    Aug

  • 08

    Aug

CHFS

CHF Solutions

$1.50

0.01 (0.67%)

09:38
07/23/18
07/23
09:38
07/23/18
09:38
Hot Stocks
CHF Solutions shares rise in early trade after VA contract circulated »

Shares of CHF Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPLO

Diplomat Pharmacy

$22.35

-2.575 (-10.33%)

09:35
07/23/18
07/23
09:35
07/23/18
09:35
Recommendations
Diplomat Pharmacy analyst commentary  »

Diplomat Pharmacy recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

09:35
07/23/18
07/23
09:35
07/23/18
09:35
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

09:35
07/23/18
07/23
09:35
07/23/18
09:35
General news
U.S. existing home sales preview: »

U.S. existing home sales…

UGP

Ultrapar

$11.42

0.375 (3.40%)

09:33
07/23/18
07/23
09:33
07/23/18
09:33
Downgrade
Ultrapar rating change  »

Ultrapar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZZ

Cosan

$8.32

0.105 (1.28%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Downgrade
Cosan rating change  »

Cosan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$45.23

0.26 (0.58%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

, CYH

Community Health

$2.72

-0.055 (-1.99%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Recommendations
LifePoint, Community Health, Apollo Global, HCA Healthcare analyst commentary  »

Deal activity could pick…

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

CYH

Community Health

$2.72

-0.055 (-1.99%)

APO

Apollo Global

$35.39

-0.22 (-0.62%)

HCA

HCA Healthcare

$108.01

0.31 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 27

    Jul

  • 27

    Jul

  • 02

    Aug

  • 22

    Aug

BIDU

Baidu

$260.00

-2.32 (-0.88%)

09:31
07/23/18
07/23
09:31
07/23/18
09:31
Downgrade
Baidu rating change  »

Baidu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.